phrykt

Immunocore Holdings plc (IMCR): who owns it and who trades it

As of Nov 16, 2026, IMCR insiders reported 10 open-market sales worth $5.6M and no purchases in the last 12 months, with 89% of the sale value made under pre-set 10b5-1 plans. The largest seller was David M Berman (HEAD OF R&D), with $5.2M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Immunocore Holdings

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns IMCR

136 funds and institutions reported IMCR shares worth $1.7B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Wellington Management Group LLP with 11.2%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Wellington Management Group LLP11.2%
Rtw Investments, LP9.6%
FMR LLC (Fidelity)8.5%
Primecap Management Co7.2%
Bellevue Group AG5.5%
Tang Capital Management LLC5.2%
Vestal Point Capital, LP3.5%
Two Sigma Investments, LP3.2%
Millennium Management LLC3.1%
Armistice Capital, LLC2.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Wellington Management Group LLP5.72M11.25%$182M+22%
Rtw Investments, LP4.87M9.57%$155MNo change
FMR LLC (Fidelity)4.31M8.47%$137M-11%
Primecap Management Co3.64M7.15%$116M-1%
Bellevue Group AG2.79M5.48%$88.5M-0%
Tang Capital Management LLC2.65M5.21%$84.1MNo change
Vestal Point Capital, LP1.80M3.54%$57.1M-35%
Two Sigma Investments, LP1.65M3.24%$52.4M+61%
Millennium Management LLC1.60M3.14%$50.7M+29%
Armistice Capital, LLC1.43M2.81%$45.3M+20%
Caligan Partners LP1.38M2.72%$43.9M–
Kynam Capital Management, LP1.38M2.70%$43.7M+55%
Bvf Inc1.29M2.54%$41.1MNo change
Acadian Asset Management LLC1.21M2.38%$38.4M+141%
Trails Edge Capital Partners, LP1.06M2.09%$33.8M+56%
BlackRock, Inc.1.00M1.98%$31.9M+53%
Point72 Asset Management, L.P.990,2801.95%$31.4M-10%
T. Rowe Price Associates831,0681.63%$26.4M-10%
Jupiter Topco LLC709,0221.39%$22.5M–
Cantor Fitzgerald, L. P.680,2001.34%$21.6M+172%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, IMCR insiders reported $0 of open-market purchases and $5.6M of sales. 89% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$5.6M
10 trades, 4 people
Sales under a 10b5-1 plan
89%
Share of sale value
Latest trade
Feb 18, 2026
Filed Feb 19, 2026

Purchases and sales by month

$1.3M$1.3MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Feb 18, 2026Bahija JallalCEOSale11,474$32.35$371KForm 4
Feb 18, 2026John GollVice presidentSale698$32.35$22.6KForm 4
Feb 18, 2026Leger Tina Amber StCHIEF HR OFFICERSale1,000$32.35$32.4KForm 4
Feb 18, 2026David M BermanHEAD OF R&DSale5,965$32.35$193KForm 4
Dec 5, 2025David M BermanHEAD OF R&DSale plan572$40.14$23KForm 4
Dec 4, 2025David M BermanHEAD OF R&DSale plan31,341$40.26$1.3MForm 4
Nov 28, 2025David M BermanHEAD OF R&DSale plan5,521$40.09$221KForm 4
Nov 26, 2025David M BermanHEAD OF R&DSale plan69,404$40.12$2.8MForm 4
Nov 25, 2025David M BermanHEAD OF R&DSale plan18,020$40.03$721KForm 4
Nov 24, 2025David M BermanHEAD OF R&DSale plan100$40.00$4KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
David M BermanHEAD OF R&D–$5.2MFeb 18, 2026
Bahija JallalCHIEF EXECUTIVE OFFICER, Director–$371KFeb 18, 2026
Leger Tina Amber StCHIEF HR OFFICER–$32.4KFeb 18, 2026
John GollSVP, FINANCE & CAO–$22.6KFeb 18, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

IMCR short interest

High short interest. 15.1% of IMCR shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went down 13%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 7.79M IMCR shares were sold short, 15.1% of the shares outstanding, down 0.1% from the report before. At the average daily volume of 548,595 shares, buying them all back would take about 14.2 trading days (days to cover).

Shares short, % of all shares

15.1%May 15Oct 3018.2%

Days to cover

14.2May 15Oct 3038.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20267.79M15.13%-0%548,59514.2
Oct 15, 20267.80M15.15%-1%498,40315.7
Sep 30, 20267.90M15.35%+2%381,72620.7
Sep 15, 20267.77M15.09%-0%377,89320.6
Aug 31, 20267.79M15.13%-1%374,59220.8
Aug 14, 20267.90M15.33%-4%420,02318.8
Jul 31, 20268.22M15.96%-8%472,94117.4
Jul 15, 20268.94M17.58%-1%707,79912.6
Jun 30, 20268.99M17.68%-1%718,64412.5
Jun 15, 20269.04M17.77%+3%423,00821.4
May 29, 20268.75M17.20%-2%443,95819.7
May 15, 20268.97M17.64%No change253,39935.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Immunocore Holdings company events

Immunocore Holdings filed 9 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 6, 2026.

  1. Nov 6, 2026ResultsReleased financial results. Filing
  2. Sep 14, 2026AnnouncementShared information with investors. Filing
  3. Aug 6, 2026ResultsReleased financial results. Filing
  4. May 27, 2026VoteReported shareholder vote results. Filing
  5. May 6, 2026ResultsReleased financial results. Filing
  6. Feb 25, 2026ResultsReleased financial results. Filing
  7. Jan 30, 2026LeadershipDavid Berman notified Immunocore Holdings plc of his decision to resign as Head of Research & Development of the Company, effective as of February 27, 2026, in order to pursue another opportunity. Filing
  8. Jan 9, 2026AnnouncementThe Company published an updated pipeline chart of KIMMRAK (tebentafusp) and its therapeutic candidates in development, which is filed as Exhibit 99.3 to this Current Report on Form 8-K and incorporated by reference herein. Filing
  9. Nov 28, 2025LeadershipRanjeev Krishana notified the board of directors of Immunocore Holdings plc of his decision to resign as a member of the Board and a member of the Remuneration Committee of the Board, effective immediately. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Immunocore Holdings financials

Famous investors that hold IMCR

4 of the 50 well-known investors we track reported holding IMCR in their latest 13F filing. The largest position is Steve Cohen's, worth $38.1M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 20261.26M$38.1M0.1%+27%
Israel Englander · Millennium ManagementQ3 2026839,258$25.4M0.0%-47%
Ken Griffin · Citadel AdvisorsQ3 2026267,325$8.1M0.0%-53%
Jim Simons · Renaissance TechnologiesQ3 2026267,200$8.1M0.0%+161%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named IMCR in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Bellevue Group AG13G/A4.4%
Nov 16, 2026Bellevue Group AG13G/A4.4%
Nov 9, 2026Point72 Asset Management, L.P.13G5.2%
Nov 9, 2026Point72 Asset Management, L.P.13G5.2%
Oct 7, 2026FMR LLC13G/A3.6%
Oct 7, 2026FMR LLC13G/A3.6%

Questions about Immunocore Holdings plc (IMCR) stock

Who owns the most IMCR stock?

The largest reported owner of Immunocore Holdings plc (IMCR) is Wellington Management Group LLP, with 11.2% of the company. In total, 136 funds and institutions reported holding IMCR at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are IMCR insiders buying or selling?

In the last 12 months, IMCR insiders reported no open-market purchases and 10 sales worth $5.6M. The latest trade was on Feb 18, 2026. See every trade.

What is the short interest in IMCR?

As of Oct 30, 2026, 7.79M IMCR shares were sold short, 15.1% of the shares outstanding, down 0.1% from the report before. At the average daily volume of 548,595 shares, buying them all back would take about 14.2 trading days (days to cover). See the history.

Which famous investors hold IMCR?

4 of the 50 well-known investors we track reported IMCR in their latest 13F filing, including Steve Cohen, Israel Englander, Ken Griffin. The largest position is worth $38.1M. See all holders.

Executive pay

Immunocore Holdings's chief executive was paid a total of $10.9M for the year ended Dec 31, 2025, down 15% from $12.9M the year before. In the last 12 months, Immunocore Holdings's executives and directors bought no stock on the open market and sold $5.6M.

Chief executive, total pay$10.9MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$12.2MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$3.6MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.